Commercial and Regulatory Challenges in Cancer Nanomedicine Publisher



Fateh ST¹ ; Fateh ST¹ ; Salehinajafabadi A^{3, 4} ; Aref AR^{5, 6}
Source: Functionalized Nanomaterials for Cancer Research: Applications in Treatments# Tools and Devices Published:2024

Abstract

Despite significant advances in understanding the nature of cancer and the development of effective diagnostic and therapeutic methods, cancer remains a major medical concern across the globe. Nanotechnology provides remarkable opportunities for the diagnosis and treatment of cancer. However, while many nanostructures and methods are reported, few nanomedicines have entered the market for cancer treatment. Translation, commercialization, and regulatory challenges limit the transition of cancer nanomedicines from the bench to the bedside. These challenges could be originated from the biology of cancer, the nature of nanostructures, and the players in the nanomedicine ecosystem industry. This book chapter primarily discusses the significance and extensive applicability of nanomedicines for cancer treatment, the ecosystem of the nanomedicine industry, and the workflow of nanomedicine production and commercialization. Afterward, the challenges in translation, commercialization, and regulations are explained, and potential solutions to the challenges are suggested. This chapter also includes case studies to further elucidate the challenges mentioned earlier. © 2024 Elsevier Inc. All rights reserved.